Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure

Journal of Virology

Volumn 76, Issue 18, 2002, Pages 9481-9492

  Ruff, Christian T ^a   Ray, Stuart C ^a   Kwon, Patricia ^a   Zinn, Rebekah ^a   Pendleton, Amanda ^a   Hutton, Nancy ^a   Ashworth, Roxann ^a   Gange, Stephen ^a   Quinn, Thomas C ^a   Siliciano, Robert F ^a   Persaud, Deborah ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE;

ARTICLE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; PERSISTENT VIRUS INFECTION; PHYLOGENY; PRIORITY JOURNAL; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENES, POL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INFANT; MALE; MOLECULAR SEQUENCE DATA; PHYLOGENY; SEQUENCE ANALYSIS, DNA; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0036720438     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.18.9481-9492.2002     Document Type: Article

References (40)

1. + T cells in acute HIV-1 infection
2. The challenge of viral reservoirs in HIV-1 infection
3. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection
4. Quantitation of latent tissue reservoirs and total body load in HIV-1 infection
5. Fate of HIV-1-infected T cells in vivo: Rates of transition to stable latency
6. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
7. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
8. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine
9. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
10. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
11. Confidence limits on phylogenies: An approach using the bootstrap
12. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
13. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
14. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
15. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
16. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
17. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
18. Prevalence and predictive value of intermittent viremia with combination HIV therapy
19. HIV-1 drug resistance profiles in children and adults with viral load <50 copies/ml receiving combination therapy
20. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
21. 0 lymphocytes
22. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
23. Maintaining the integrity of human immunodeficiency virus sequence databases
24. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type I infection
25. Antiretroviral resistance during successful therapy of human immunodeficiency virus type 1 infection
26. Compartments and reservoirs of HIV infection in vivo
27. Persistence of memory CD8 T cells in MHC class I-deficient mice
28. Decay characteristics of HIV-1-infected compartments during combination therapy
29. + T lymphocytes in infected children
30. Selecting models of nucleotide substitution: An application to human immunodeficiency virus 1 (HIV-1)
31. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antitretroviral therapy
32. The neighbor-joining method: A new method for reconstructing phylogenetic trees
33. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection
34. Virus "quasispecies": Making a mountain out of a molehill?
35. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro
36. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
37. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
38. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
39. Genetic characterization of rebounding HIV-1 after cessation of highly active anti-retroviral therapy
40. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy